BLASTID
BLASTID is a diagnostics company spun out of Harvard, focused on developing ultra-rapid, culture-free direct-from-blood diagnostics for bloodstream infections and sepsis. Leveraging microfluidics, live-cell super-resolution imaging, and AI-powered image analysis, BLASTID enables identification and phenotypic antibiotic susceptibility testing (AST) from whole blood in hours rather than days. Their mission is to accelerate actionable clinical insights to guide effective and timely treatment, addressing critical challenges in sepsis care and antimicrobial resistance.
Industries
N/A
BLASTID
135 William T. Morrissey Blvd Suite P101 Boston, MA 02125
Products
A benchtop system utilizing microfluidic capture, live-cell super-resolution imaging, and AI-driven analysis to provide culture-free, rapid pathogen identification and phenotypic antimicrobial susceptibility testing from whole blood within hours.
A benchtop system utilizing microfluidic capture, live-cell super-resolution imaging, and AI-driven analysis to provide culture-free, rapid pathogen identification and phenotypic antimicrobial susceptibility testing from whole blood within hours.
Expertise Areas
- Single-cell blood diagnostics
- Rapid antimicrobial susceptibility testing
- Microfluidics for rare cell capture
- AI-based pathogen identification
Key Technologies
- Microfluidics
- Super-resolution microscopy
- Machine learning for image analysis
- Single-cell assays
Key People
News & Updates
Publication details CAMPER, a machine learning-based framework for antimicrobial peptide discovery targeting MRSA persisters.
BLASTID co-founder leads multi-institutional ARPA-H award to advance microscopy, microfluidics, and machine learning for rapid bacterial diagnostics and antibiotic discovery.
ARPA-H awarded up to $104 million for development of ultra-high-speed diagnostic and screening platforms by a team including BLASTID.
Poster presentation demonstrated ultra-rapid pathogen isolation from blood samples and compatibility with FDA-approved automated AST system.
Announced successful proof-of-concept for direct-from-blood pathogen isolation, enrichment, and phenotypic AST, presented at the ADLM 2025 Conference.
Publication details CAMPER, a machine learning-based framework for antimicrobial peptide discovery targeting MRSA persisters.
BLASTID co-founder leads multi-institutional ARPA-H award to advance microscopy, microfluidics, and machine learning for rapid bacterial diagnostics and antibiotic discovery.
ARPA-H awarded up to $104 million for development of ultra-high-speed diagnostic and screening platforms by a team including BLASTID.
Poster presentation demonstrated ultra-rapid pathogen isolation from blood samples and compatibility with FDA-approved automated AST system.
Announced successful proof-of-concept for direct-from-blood pathogen isolation, enrichment, and phenotypic AST, presented at the ADLM 2025 Conference.